Faculty

Karyn Lee Boyar headshot

Karyn Lee Boyar

Clinical Assistant Professor

1 212 992 9361

433 First Avenue
Room 415
New York, NY 10010
United States

expand all

collapse all

Professional overview

Karyn Boyar is an educator and family nurse practitioner specializing in Neurology and long term care. She is an Assistant Clinical Professor at the New York University College of Nursing, teaching both didactic and clinical courses and simulation. Dr. Boyar earned her DNP from Pace University in 2014, Family Nurse Practitioner /Master’s degree in Nursing Science from Pace University in 2002 and her BS from Pace in 2001. She has over 20 years’ experience in healthcare and over 10 years’ experience in the clinical care and management of patients with Parkinson’s disease and Dystonia. Her background includes work on many research trials including original research on diet in the management of Parkinson’s disease. Dr. Boyar has created comprehensive outreach initiatives for people with Parkinson’s disease that include community symposia, support groups and educational lectures and materials. She also created and taught unique movement classes with live music, designed for people with Parkinson’s disease. Before joining the faculty at the Rory Meyers College of Nursing, Ms Boyar was Clinical Specialty Coordinator at Mount Sinai School of Medicine and was the designated Outreach Coordinator for the National Parkinson Center of Excellence at the Robert and John M. Benheim Center for Movement Disorders.

Education

DNP
FNP-BC
RN

Honors and awards

Hillman Scholar

Specialties

Primary care
Home care
Neurology

Professional membership

Sigma Theta Tau
Eastern Nursing Research Society
American Nurses Association
Hillman Alumni Association
National League of Nursing

Publications

Publications

Making QSEN visible in the classroom: Innovative use of in-class care mapping activity

Rodriguez, K., Boyar, K., Weidel, J., & Ea, E. (2016). QSEN Institute Teaching Strategy (online).

Essential tremor versus parkinson disease: Make the right diagnosis

Boyar, K. (2014). The Nurse Practitioner, 39(9), 13-16. 10.1097/01.NPR.0000452984.51256.1a

A randomized clinical trial of high-dosage coenzyme Q10 in early parkinson disease no evidence of benefit

Failed generating bibliography.
Abstract
IMPORTANCE Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A previous phase II study suggested possible clinical benefit. OBJECTIVE To examine whether CoQ10 could slow disease progression in early PD. DESIGN, SETTING, AND PARTICIPANTS A phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American sites consisting of participants 30 years of age or older who received a diagnosis of PD within 5 years and who had the following inclusion criteria: the presence of a rest tremor, bradykinesia, and rigidity; a modified Hoehn and Yahr stage of 2.5 or less; and no anticipated need for dopaminergic therapy within 3 months. Exclusion criteria included the use of any PD medication within 60 days, the use of any symptomatic PD medication for more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson’s Disease Rating Scale (UPDRS) rest tremor score of 3 or greater for any limb, a Mini-Mental State Examination score of 25 or less, a history of stroke, the use of certain supplements, and substantial recent exposure to CoQ10. Of 696 participants screened, 78 were found to be ineligible, and 18 declined participation. INTERVENTIONS The remaining 600 participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E. MAIN OUTCOMES AND MEASURES Participants were observed for 16 months or until a disability requiring dopaminergic treatment. The prospectively defined primary outcome measure was the change in total UPDRS score (Parts I-III) from baseline to final visit. The study was powered to detect a 3-point difference between an active treatment and placebo. RESULTS The baseline characteristics of the participants were well balanced, the mean age was 62.5 years, 66%of participants were male, and the mean baseline total UPDRS score was 22.7. A total of 267 participants required treatment (94 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely. Treatments were well tolerated with no safety concerns. The study was terminated after a prespecified futility criterion was reached. At study termination, both active treatment groups showed slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores from baseline to final visit were 6.9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P =.49 relative to placebo), and 8.0 points (2400 mg/d of CoQ10; P =.21 relative to placebo). CONCLUSIONS AND RELEVANCE Coenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00740714.

R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation

Nichols, W. C., Marek, D. K., Pauciulo, M. W., Pankratz, N., Halter, C. A., Rudolph, A., Shults, C. W., Wojcieszek, J., Foroud, T., Shults, C., Marshall, F., Oakes, D., Rudolph, A., Shinaman, A., Marder, K., Conneally, P. M., Foroud, T., Halter, C., Lyons, K., Siemers, E., Factor, S., Higgins, D., Evans, S., Shill, H., Stacy, M., Danielson, J., Marlor, L., Williamson, K., Jankovic, J., Hunter, C., Simon, D., Ryan, P., Scollins, L., Saunders-Pullman, R., Boyar, K., Costan-Toth, C., Ohmann, E., Sudarsky, L., Joubert, C., Friedman, J., Chou, K., Fernandez, H., Lannon, M., Galvez-Jimenez, N., Podichetty, A., Lewitt, P., DeAngelis, M., O’Brien, C., Seeberger, L., Dingmann, C., Judd, D., Marder, K., Fraser, J., Harris, J., Bertoni, J., Peterson, C., Chouinard, S., Panisset, M., Hall, J., Poiffaut, H., Calabrese, V., Roberge, P., Wojcieszek, J., Belden, J., Halter, C., Jennings, D., Marek, K., Mendick, S., Reich, S., Dunlop, B., Jog, M., Horn, C., Rao, J., Cook, M., Uitti, R., Turk, M., Ajax, T., Mannetter, J., Panisset, M., Hall, J., Sethi, K., Carpenter, J., Ligon, K., Narayan, S., Woodward, L., Blindauer, K., Petit, J., Elmer, L., Aiken, E., Davis, K., Schell, C., Wilson, S., Velickovic, M., Koller, W., Phipps, S., Feigin, A., Gordon, M., Hamann, J., Licari, E., Marotta-Kollarus, M., Shannon, B., Winnick, R., Simuni, T., Kaczmarek, A., Williams, K., Wolff, M., Fernandez, M., Hubble, J., Kostyk, S., Campbell, A., Reider, C., Camicioli, R., Carter, J., Andrews, P., Morehouse, S., Stone, C., Mendis, T., Grimes, D., Gray, P., Haas, K., Sutton, J., Hutchinson, B., Young, J., Rajput, A., Rajput, A., Klassen, L., Shirley, T., Manyam, B., Simpson, P., Whetteckey, J., Wulbrecht, B., Truong, D., Pathak, M., Luong, N., Tra, T., Tran, A., Vo, J., Lang, A., Kleiner-Fisman, G., Nieves, A., So, J., Podskalny, G., Giffin, L., Atchison, P., Allen, C., Martin, W., Wieler, M., Suchowersky, O., Klimek, M., Hermanowicz, N., Niswonger, S., Shults, C., Fontaine, D., Aminoff, M., Christine, C., Diminno, M., Hevezi, J., Dalvi, A., Kang, U., Richman, J., Uy, S., Young, J., Dalvi, A., Sahay, A., Schwieterman, D., Leehey, M., Culver, S., Derian, T., Demarcaida, T., Belber, S., Rodnitzky, R., Dobson, J., Pahwa, R., Lyons, K., Gales, T., Thomas, S., Shulman, L., Weiner, W., Dustin, K., Singer, C., Koller, W., Lyons, K., Weiner, W., Zelaya, L., Tuite, P., Hagen, V., Rolandelli, S., Schacherer, R., Gordon, P., Werner, J., Serrano, C., Roque, S., Kurlan, R., Berry, D., Gardiner, I., Hauser, R., Sanchez-Ramos, J., Zesiewicz, T., Delgado, H., Price, K., Rodriguez, P., Pfeiffer, R., Davis, L., Pfeiffer, B., Dewey, R., Hayward, B., Meacham, M., Walker, F., Hunt, V., Racette, B., Good, L., Rundle, M., Oakes, D., Watts, A., Wang, A., Ross, T., Bennett, S., Kamp, D., & Julian-Baros, E. (2007). Movement Disorders, 22(2), 254-257. 10.1002/mds.21233
Abstract
Mutations in LRRK2 were first reported as causing Parkinson's disease (PD) in late 2004. Since then, approximately a dozen LRRK2 substitutions have been identified that are believed to be pathogenic mutations. The substitution of adenine for guanine at nucleotide 4541 (4541G>A) in LRRK2 was recently reported. This substitution resulted in the replacement of an arginine at position 1514 with a glutamine (R1514Q). Although this substitution was not found in a large cohort of controls, its pathogenicity could not be verified. We have now genotyped the R1514Q substitution in a sample of 954 PD patients from 429 multiplex PD families. This substitution was identified in 1.8% of the PD patients; however, the majority of the PD sibships segregating this substitution were discordant for this putative mutation. In addition, the R1514Q substitution was detected in 1.4% of neurologically evaluated, control individuals. These data suggest that the R1514Q variant is not a pathogenic LRRK2 mutation. We believe it is imperative that the causative nature of any newly identified genetic variant be determined before it is included in any panel for diagnostic testing.

Mutations in LRRK2 other than G2019S are rare in a north-American based sample of familial Parkinson's didease

Pankratz, N., Pauciulo, M. W., Elsaesser, V. E., Marek, D. K., Halter, C. A., Rudolph, A., Shults, C. W., Foroud, T., Nichols, W. C., Shults, C., Marshall, F., Oakes, D., Shinaman, A., Marder, K., Conneally, P. M., Lyons, K., Siemers, E., Factor, S., Higgins, D., Evans, S., Shill, H., Stacy, M., Danielson, J., Marlor, L., Williamson, K., Jankovic, J., Hunter, C., Simon, D., Ryan, P., Scollins, L., Saunders-Pullman, R., Boyar, K., Costan-Toth, C., Ohmann, E., Sudarsky, L., Joubert, C., Friedman, J., Chou, K., Fernandez, H., Lannon, M., Galvez-Jimenez, N., Podichetty, A., Lewitt, P., DeAngelis, M., O’Brien, C., Seeberger, L., Dingmann, C., Judd, D., Fraser, J., Harris, J., Bertoni, J., Peterson, C., Chouinard, S., Panisset, M., Hall, J., Poiffaut, H., Calabrese, V., Roberge, P., Wojcieszek, J., Belden, J., Halter, C., Jennings, D., Marek, K., Mendick, S., Reich, S., Dunlop, B., Jog, M., Horn, C., Rao, J., Cook, M., Uitti, R., Turk, M., Ajax, T., Mannetter, J., Sethi, K., Carpenter, J., Ligon, K., Narayan, S., Woodward, L., Blindauer, K., Petit, J., Elmer, L., Aiken, E., Davis, K., Schell, C., Wilson, S., Velickovic, M., Koller, W., Phipps, S., Feigin, A., Gordon, M., Hamann, J., Licari, E., Marotta-Kollarus, M., Shannon, B., Winnick, R., Simuni, T., Kaczmarek, A., & Williams, K. (2006). Movement Disorders, 21(12), 2257-2260. 10.1002/mds.21162
Abstract
A total of 956 individuals with Parkinson's disease (PD) from 430 multiplex PD pedigrees were screened for 12 previously reported, pathogenic LRRK2 mutations: R793M, L1114L, I1371V, R1441C, R1441G, R1441H, Y1699C, M1869T, I2012T, I2020T, G2385R, and IVS31 +3G>A. Previous screening identified the LRRK2 G2019S mutation in 5% of our families. Only 1 of the 12 newly screened mutations, R1441C, was detected in a single family in our patient cohort. These results indicate that, although the G2019S mutation remains the most common mutation identified in familial PD patients, other mutations in LRRK2 are infrequent

Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia

Pankratz, N., Byder, L., Halter, C., Rudolph, A., Shults, C. W., Conneally, P. M., Foroud, T., Nichols, W. C., Lyons, K., Marder, K., Marshall, F., Oakes, D., Rudolph, A., Shinaman, A., Siemers, E., Wojcieszek, J., Belden, J., Carter, J., Camicioli, R., Andrews, P., Panisset, M., Hall, J., Hubble, J., Fernandez, M., Reider, C., Rajput, A., Rajput, A., Shirley, T., Mendis, T., Grimes, D. A., Gray, P., Ramos, C. S., Roque, S., Pfeiffer, R., Pfeiffer, B., Elmer, L., Davis, K., Friedman, J., Fernandez, H., Lannon, M., Reich, S., Dunlop, B., Seeberger, L., O’Brien, C., Judd, D., Hauser, R., Zesiewicz, T., Delgado, H., Fontaine, D., Jennings, D., Marek, K., Mendick, S., Aminoff, M., DiMinno, M., Lewitt, P., De Angelis, M., Pahwa, R., Thomas, S., Truong, D., Pathak, M., Tran, A., Rodnitzky, R., Dobson, J., Koller, W., Weiner, W., Lyons, K., Kurlan, R., Berry, D., Bertoni, J., Peterson, C., Martin, W., Wieler, M., Tuite, P., Schacherer, R., Harris, J., Jankovic, J., Hunter, C., Lang, A., Kleimer-Fisman, G., Nieves, A., So, J., Factor, S., Evans, S., Manyam, B., Wulbrecht, B., Walker, F., Hunt, V., Gordon, M. F., Hamman, J., Kang, U. J., Young, J., Blindauer, K., Petit, J., Rao, J., Cook, M., Stacy, M., Williamson, K., Pullman, R. S., & Boyar, K. (2006). Movement Disorders, 21(1), 45-49. 10.1002/mds.20663
Abstract
The ε4 allele of the apolipoprotein E gene (APOE4) has been consistently associated with a greater risk of Alzheimer's disease (AD) as well as an earlier onset of AD. It is possible that APOE4 may also play a role in the etiology of other neurodegenerative disorders, such as Parkinson's disease (PD). APOE genotype, age of onset, disease duration, smoking history, and dementia status were collected for families with PD, yielding 324 Caucasian families with complete information. Logistic regression employing one individual per family and including age of onset and disease duration as covariates demonstrated a significantly increased risk of dementia for those individuals having inherited at least one ε4 allele (OR = 3.37; P = 0.002). Survival analyses also demonstrated a significantly earlier age of onset for those subjects with at least one ε4 allele (59.7 years) as compared with those homozygous for the more common ε3 allele (62.4 years; P = 0.009). Thus, consistent with previous studies, we find evidence that the presence of an ε4 allele results in significantly earlier onset of PD and a greater likelihood of dementia. It appears the similarities between PD and AD may be due to an overlap in the diseases' genetic etiology.

Treatment of Parkinson disease with diet-induced hyperketonemia: A feasibility study

VanItallie, T. B., Nonas, C., Di Rocco, A., Boyar, K., Hyams, K., & Heymsfield, S. B. (2005). Neurology, 64(4), 728-730.
Abstract
Ketones may bypass the defect in complex I activity implicated in Parkinson disease (PD). Five of seven volunteers with PD were able to prepare a "hyperketogenic" diet at home and adhere to it for 28 days. Substituting unsaturated for saturated fats appeared to prevent cholesterol increases in four volunteers. Unified Parkinson's Disease Rating Scale scores improved in all five during hyperketonemia, but a placebo effect was not ruled out.

Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease

Nichols, W. C., Uniacke, S. K., Pankratz, N., Reed, T., Simon, D. K., Halter, C., Rudolph, A., Shults, C. W., Conneally, P. M., Foroud, T., Wojcieszek, J., Belden, J., Carter, J., Camicioli, R., Andrews, P., Panisset, M., Hall, J., Hubble, J., Fernandez, M., Reider, C., Rajput, A., Rajput, A., Shirley, T., Mendis, T., Grimes, D. A., Gray, P., Ramos, C. S., Roque, S., Pfeiffer, R., Pfeiffer, B., Elmer, L., Davis, K., Friedman, J., Fernandez, H., Lannon, M., Reich, S., Dunlop, B., Seeberger, L., O’Brien, C., Judd, D., Hauser, R., Zesiewicz, T., Delgado, H., Shults, C., Fontaine, D., Jennings, D., Marek, K., Mendick, S., Aminoff, M., DiMinno, M., Lewitt, P., DeAngelis, M., Pahwa, R., Thomas, S., Truong, D., Pathak, M., Tran, A., Rodnitzky, R., Dobson, J., Koller, W., Weiner, W., Lyons, K., Kurlan, R., Berry, D., Bertoni, J., Peterson, C., Martin, W., Tuite, P., Schacherer, R., Marder, K., Harris, J., Jankovic, J., Hunter, C., Lang, A., Kleimer-Fisman, G., Nieves, A., So, J., Factor, S., Evans, S., Manyam, B., Wulbrecht, B., Walker, F., Hunt, V., Gordon, M. F., Hamman, J., Kang, U. J., Young, J., Blindauer, K., Petit, J., Rao, J., Cook, M., Stacy, M., Williamson, K., Pullman, R. S., Boyar, K., Leehey, M., Derian, T., Gordon, P., & Werner, J. (2004). Movement Disorders, 19(6), 649-655. 10.1002/mds.20097
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder in humans with wide variability in the age of disease onset. Although the disease has been thought previously to occur sporadically in most patients, there is increasing evidence of a genetic contribution to the disorder. Recently, a polymorphic variant within intron 6 of the Nurr1 gene was reported to be associated with sporadic and familial PD. In an effort to identify susceptibility genes for PD, we have collected 783 PD patients from 372 families and 397 healthy controls from 217 families. PD patients and healthy controls were genotyped for the intron 6 insertion polymorphism by BseRI restriction endonuclease digestion. No significant difference in either homozygosity or heterozygosity for the 7048G7049 (IVS6 1361 +16insG) polymorphism was detected in the PD patient cohort as compared with the panel of healthy controls. Moreover, direct sequencing of exon 1 of the Nurr1 gene in PD patients failed to detect either of the two recently reported Nurr1 mutations identified in a small subset of a PD patient cohort. Taken together, these data suggest that genetic alteration at the Nurr1 locus is not a significant risk factor for the development of Parkinson's disease in our large sample of familial PD patients.

Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families

Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Murrell, J., Rudolph, A., Shults, C. W., Conneally, P. M., Foroud, T., Truong, D., Pathak, M., Tran, A., Rodnitzky, R., Dobson, J., Koller, W., Weiner, W., Lyons, K., Kurlan, R., Berry, D., Bertoni, J., Peterson, C., Martin, W., Wieler, M., Tuite, P., Schacherer, R., Marder, K., Harris, J., Jankovic, J., Hunter, C., Lang, A., Kleimer-Fisman, G., Nieves, A., So, J., Factor, S., Evans, S., Manyam, B., Wulbrecht, B., Walker, F., Hunt, V., Gordon, M. F., Hamman, J., Kang, U. J., Young, J., Blindauer, K., Petit, J., Rao, J., Cook, M., Stacy, M., Williamson, K., Pullman, R. S., Boyar, K., Leehey, M., Derian, T., Gordon, P., Werner, J., Racette, B., Good, L., Simon, D., Scollins, L., Schwieterman, D., Dewey, R., Meacham, M., Sutton, J., Hutchinson, B., Jog, M., Horn, C., Sethi, K., Carpenter, J., Atchison, P., Rolli, S., Sudarsky, L., Corwin, C., Velickovic, M., Phipps, S., Simuni, T., Kaczmarek, A., Hermanowicz, N., Niswonger, S., Feigin, A., Shannon, B., Calabrese, V., Roberge, P., Homes, H., Shulman, L., Dustin, K., Ajax, T., Mannetter, J., Podskalny, G. D., Giffin, L., Uitti, R., & Turk, M. F. (2003). Human Molecular Genetics, 12(20), 2599-2608. 10.1093/hmg/ddg270
Abstract
Parkinson disease (PD) is the second most common neurodegenerative disorder. We studied 754 affected individuals, comprising 425 sibling pairs, to identify PD susceptibility genes. Screening of the parkin gene was performed in a subset of the sample having earlier age of PD onset or a positive LOD score with a marker in the parkin gene. All subjects were evaluated using a rigorous neurological assessment. Two diagnostic models were considered for genome-wide, non-parametric linkage analyses. Model I included only those individuals with a more stringent diagnosis of verified PD (216 sibling pairs) and resulted in a maximum LOD score of 3.4 on chromosome 2. Model II included all affected individuals (425 sibling pairs) and yielded a LOD score of 3.1 on the X chromosome. Our large sample was then employed to test for gene-by-gene (epistatic) interactions. A genome screen using the 23 families with PD patients having a mutation in only one allele of the parkin gene detected evidence of linkage to chromosome 10 (LOD = 2.3). The 85 families with a very strong family history of PD were employed in a genome screen and, in addition to strong evidence of linkage to chromosome 2 (LOD = 4.9), also produced a LOD of 2.4 on chromosome 14. A genome screen performed in the 277 families without a strong family history of PD detected linkage to chromosomes 10 (LOD = 2.4) and X (LOD = 3.2). These findings demonstrate consistent evidence of linkage to chromosomes 2 and X and also support the hypothesis that gene-by-gene interactions are important in PD susceptibility.

Significant linkage of Parkinson disease to chromosome 2q36-37

Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Rudolph, A., Shults, C., Conneally, P. M., Foroud, T., Golbe, L., Koller, W., Lyons, K., Marder, K., Marshall, F., Oakes, D., Shinaman, A., Siemers, E., Wojcieszek, J., Belden, J., Carter, J., Camicioli, R., Andrews, P., Fernandez, M., Hubble, J., Reider, C., Rajput, A., Rajput, A., Shirley, T., Panisset, M., Hall, J., Mendis, T., Grimes, D. A., Gray, P., Ramos, C. S., Roque, S., Reich, S., Dunlop, B., Hauser, R., Sanchez-Ramos, J., Zesiewicz, T., Delgado, H., Friedman, J., Fernandez, H., Lannon, M., Seeberger, L., O’Brien, C., Judd, D., Elmer, L., Davis, K., Fontaine, D., Pfeiffer, R., Pfeiffer, B., Aminoff, M., DiMinno, M., Truong, D., Pathak, M., Tran, A., Rodnitzky, R., Dobson, J., Pahwa, R., Thomas, S., Jennings, D., Marek, K., Mendick, S., Harris, J., Weiner, W., Kurlan, R., Berry, D., Lewitt, P., DeAngelis, M., Tuite, P., Schacherer, R., Martin, W., Wieler, M., Manyam, B., Simpson, P., Bertoni, J., Peterson, C., Gordon, M. F., Hamann, J., Jankovic, J., Hunter, C., Factor, S., Evans, S., Nieves, A., So, J., Stacy, M., Williamson, K., Walker, F., Hunt, V., Kang, U. J., Uy, S., Blindauer, K., Petit, J., Simon, D., Scollins, L., Pullman, R. S., Boyar, K., Gordon, P., & Werner, J. (2003). American Journal of Human Genetics, 72(4), 1053-1057. 10.1086/374383
Abstract
Parkinson disease (PD) is the second most common neurodegenerative disorder, surpassed in frequency only by Alzheimer disease. Elsewhere we have reported linkage to chromosome 2q in a sample of sibling pairs with PD. We have now expanded our sample to include 150 families meeting our strictest diagnostic definition of verified PD. To further delineate the chromosome 2q linkage, we have performed analyses using only those pedigrees with the strongest family history of PD. Linkage analyses in this subset of 65 pedigrees generated a LOD score of 5.1, which was obtained using an autosomal dominant model of disease transmission. This result strongly suggests that variation in a gene on chromosome 2q36-37 contributes to PD susceptibility.